Vertex Pharmaceuticals Inc / Ma (VRTX) Financials: Revenue, Profit & Balance Sheet

By the Company Financials Data Editorial Team · Last updated: October 2026

Vertex Pharmaceuticals Inc / Ma files annual reports with the U.S. Securities and Exchange Commission, and this page organises the headline numbers from those filings in one place. The most recent fiscal year covered here is fiscal 2025. In that reporting cycle the company recorded revenue of $12.00 billion and net income of $3.95 billion. Everything on this page is drawn from the SEC EDGAR XBRL company facts dataset, which republishes the exact tagged values companies submit in their 10-K annual filings, so the figures can be checked against the original documents at any time. Data: SEC EDGAR company facts, retrieved October 2026; fiscal years are shown as filed by the company.

Vertex Pharmaceuticals Inc / Ma financial results in detail

Revenue in fiscal 2025 was $12.00 billion, up 8.9% from $11.02 billion in fiscal 2024. Over the three years from fiscal 2022, when revenue was $8.93 billion, the compound annual growth rate works out to about 10.4% a year. The earliest annual revenue figure in the table on this page is $175.5 million for fiscal 2008, so readers can judge for themselves whether the most recent year continues a longer pattern or breaks from it. Revenue is the top line of the income statement: it records what customers paid for goods and services before any costs are deducted, which is why analysts pair it with the profit measures below rather than reading it on its own.

Vertex Pharmaceuticals Inc / Ma reported net income of $3.95 billion in fiscal 2025, a net profit margin of about 32.9% on that year's revenue. Net income is the bottom line: revenue minus the cost of goods sold, operating expenses, interest and taxes. Operating income came to $4.17 billion, and the gap between operating income and net income is where interest and tax sit, so comparing the two tells you how much financing and tax shaped the final result. Diluted earnings per share were $15.32 in fiscal 2025. Diluted EPS spreads net income across all shares that could exist if convertible instruments were exercised, making it the most conservative per-share profit figure in the filing.

Balance sheet strength

On the balance sheet, Vertex Pharmaceuticals Inc / Ma held total assets of $25.64 billion at the end of fiscal 2025. Stockholders' equity — the owners' residual claim after liabilities — stood at $18.67 billion, meaning equity financed about 72.8% of the asset base. Cash and cash equivalents were $5.08 billion, the most liquid reserve the company can draw on without selling anything or borrowing. Balance-sheet figures are a snapshot at the fiscal year-end date, not an average across the year, which is why they are labelled with the fiscal year they were filed under.

Cash flow and free cash flow

Operating cash flow in the most recent reported year was $3.63 billion. Cash flow and profit are different things: net income includes non-cash charges such as depreciation, while operating cash flow records cash actually generated by the business. After capital expenditures, free cash flow — a calculated figure on this site, defined as operating cash flow minus payments to acquire property, plant and equipment — was $3.19 billion in fiscal 2025. Free cash flow is the cash available for dividends, buybacks, debt repayment or reinvestment once the asset base has been maintained, which is why it is watched so closely. When operating cash flow persistently exceeds net income, it usually signals heavy non-cash charges or disciplined working capital; when it persistently trails net income, readers should look in the 10-K for receivables or inventory building faster than sales.

Frequently asked questions

Compare Vertex Pharmaceuticals Inc / Ma with other large filers: Marathon Petroleum Corporation (MPC) · Blackstone Inc. (BX) · S&P Global Inc. (SPGI). Return to the full company directory or the homepage.